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Repeated, extreme, or traumatic stressors can elicit pathological effects leading to many negative
physical and psychological outcomes. Stressors can precipitate the onset of psychiatric diseases, or
exacerbate pre-existing disorders including various anxiety and mood disorders. As stressors can
negatively impact human psychiatric health, it is essential to identify neurochemicals that may confer
protection from the negative sequelae of repeated or extreme stress exposure. Elucidating the neuro-
biological underpinnings of stress resilience will enhance our ability to promote resilience to, or recovery
from, stress-related psychiatric disease. Herein, we will review the evidence for neuropeptide Y as an
endogenous mediator of resilience and its potential relevance for the treatment of stress-related psy-
chiatric diseases.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction
Stressors elicit a cascade of neuronal, endocrine, and behavioral
responses that promote homoeostatic adaptation to changing or
threatening environments. Stressors maintained over prolonged
periods of time or perceived as extreme can lead to maladaptive
responses within stress-integrative circuitry. Pathological neuro-
chemical and behavioral mechanisms can thenmanifest in the form
of stress-related psychiatric diseases including anxiety disorders,
post-traumatic stress disorder (PTSD), and depression. Neuropep-
tides have been shown to be inﬂuential neuromodulators of stress-
related emotionality (Kormos and Gaszner, 2013). A growing body
of evidence supports a role for neuropeptide Y (NPY) as a protective
neurochemical that mediates stress resilience. NPY is a 36-amino
acid peptide derived from preproNPY and belonging to a family
that also includes pancreatic polypeptide (PP) and peptide YY (PYY)
(Larhammar et al., 1993). NPY is highly conserved across mamma-
lian species and is expressed throughout the central nervous sys-
tem (CNS) (Larhammar et al., 2001; Adrian et al., 1983; Allen et al.,
1983; Lundberg and Hokfelt, 1986; Hirsch and Zukowska, 2012). Inlogy and Physiology, Drexel
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.M. Enman), esther_sabban@
du (P. McGonigle), elisabeth.
Inc. This is an open access article uthe periphery, NPY is expressed primarily in sympathetic ganglia,
the adrenal medulla, and in platelets (Larhammar et al., 2001;
Adrian et al., 1983; Allen et al., 1983; Lundberg and Hokfelt, 1986;
Hirsch and Zukowska, 2012). NPY is the most abundant and
widely distributed neuropeptide in the human brain (Adrian et al.,
1983), and has been shown to have a signiﬁcant impact on brain
activity. In the CNS, NPY and its receptors (Y1, Y2, Y4, Y5) play
important roles in the control of food intake, energy homeostasis,
pain, and many behavioral and physiological processes associated
with stress and stress resilience (Hirsch and Zukowska, 2012;
Brothers and Wahlestedt, 2010). In this review, we will discuss
the role of NPY in stress-related behaviors and its relevance to
select psychiatric disorders.2. Neuropeptide Y (NPY)
2.1. NPY and NPY receptor subtypes in the brain
NPY immunopositive cell bodies and ﬁbers are generally found
in cortical, limbic, hypothalamic, and brainstem regions (Allen et al.,
1983). Expression of NPY in the human and rodent brain is similar,
with abundant NPY mRNA or immunoreactivity located in the
neocortex, amygdala, hippocampus, basal ganglia, hypothalamus,
periaqueductal grey, dorsal raphe nucleus, and the A1-3 and A6
noradrenergic cells groups in the brainstem (Adrian et al., 1983;
Allen et al., 1983; Caberlotto et al., 2000; Wahlestedt et al., 1989;
Yamazoe et al., 1985; de Quidt and Emson, 1986; de Quidt andnder the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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subtypes of G-protein coupled receptors termed Y1, Y2, Y4, and Y5.
Y6 receptors are expressed in the mouse brain, but this isoform is
absent in the rat and nonfunctional in human and non-human
primates (Larhammar and Salaneck, 2004). Autoradiographic and
immunohistochemical examinations indicate that Y1 and Y2 re-
ceptors (Y1R and Y2R) exhibit the greatest expression in the brain,
whereas lower levels of Y4 and Y5 receptors (Y4R and Y5R) are also
present (Dumont et al., 1993; Stanic et al., 2006; Stanic et al., 2011;
Dumont et al.,1998; Kask et al., 2002;Wolak et al., 2003). Signiﬁcant
differences in the distribution of NPY receptors are detectable be-
tween the rodent and human brain, warranting caution in the
generalization of the role of NPY receptors from preclinical animal
models to humans (Dumont et al., 1998). NPY receptors can couple
to various effectors systems by associating with inhibitory Gi/o
proteins (see review (Sah and Geracioti, 2013)). NPY receptors
inhibit adenylyl cyclase and the accumulation of cAMP, mobilize
calcium through phospholipase C and phosphatidylinositol
3-kinase activity, and have effects onmultiple ion channels (Sah and
Geracioti, 2013). Within stress responsive brain regions such as the
cortex, amygdala, hypothalamus, and locus coeruleus, NPY re-
ceptors are localized on or impact the function of neurons
expressing GABA, glutamate, corticotropin-releasing factor (CRF),
and norepinephrine (NE) (Grove et al., 2000; Dimitrov et al., 2007;
Giesbrecht et al., 2010; Rostkowski et al., 2009; Illes et al., 1993;
Eaton et al., 2007). It has been hypothesized that NPY serves as a
functional “brake” to tone down the excitatory effects of pro-stress
neurotransmitters such as CRF and NE (Sah and Geracioti, 2013;
Eaton et al., 2007; Heilig et al., 1994). This hypothesis is supported
by studies demonstrating that NPY is frequently contained within
the same neuroanatomical brain structures as CRF and NE, and the
function of NPY is often physiologically and behaviorally opposite to
pro-stress neurotransmitters (reviewed in (Kask et al., 2002; Sah
and Geracioti, 2013; Sajdyk et al., 2004)). Although clear in-
teractions between NPYand pro-stress systems in the regulation of
stress-related emotionality still need to be established, it is likely
that the balance of these neuropeptides and transmitters in stress-
related circuits plays a pivotal role in mediating resilience to stress-
associated responses discussed in this review.
3. NPY in stress-related psychiatric disorders: insight from
human studies
3.1. Stress and anxiety
Human studies have identiﬁed associations between NPY and
stress resilience. In healthy human subjects, plasma NPY levels
have been shown to rise in response to stress (Morgan 3rd et al.,
2001; Morgan et al., 2000; Morgan et al., 2002). For example,
when military soldiers underwent an interrogation model of
extreme psychological stress to mimic the captive experience of
prisoners of war, higher levels of NPY following interrogation were
present in soldiers displaying lower psychological distress or
belonging to special operations forces (Morgan et al., 2000; Morgan
et al., 2002). NPY levels were positively associated with feelings of
dominance and self-conﬁdence, and superior performance under
interrogation stress (Morgan et al., 2001; Morgan et al., 2000;
Morgan et al., 2002).
Genetic variants of the preproNPY gene have been associated
with differential stress responses and emotionality (Mickey et al.,
2011; Zhou et al., 2008). Speciﬁc NPY haplotypes have been
correlated to postmortem levels of NPY mRNA in the brain, plasma
NPY concentrations, and brain activity in response to stressful
challenges (Zhou et al., 2008). Individuals possessing a genotype
associated with low NPY expression report more negativeemotional experiences during a painful stressor, exhibit greater
amygdalar reactivity in response to threat-related facial images,
and exhibit low stress resilience compared to high NPY genotype
carriers (Mickey et al., 2011; Zhou et al., 2008). Haplotype-driven
NPY expression is also inversely correlated to trait anxiety in
healthy individuals (Zhou et al., 2008).
Studies in humans with stress-related psychiatric disorders
have also revealed a role for NPY in resilience (Eaton et al., 2007;
Morales-Medina et al., 2010; Sah et al., 2009; Rasmusson et al.,
2000; Morgan et al., 2003), although the evidence stems primarily
from populations with PTSD and depression. Rodent studies have
provided a wealth of evidence for NPY in resilience to anxiety (see
below), but few human studies have been conducted to determine
the proﬁle of NPY in generalized anxiety, obsessive compulsive,
social anxiety, and panic disorders. One study found an association
between a single-nucleotide polymorphism of the NPY gene and
increased risk for generalized anxiety disorder in individuals
exposed to high stress (Amstadter et al., 2010). Genetic variants of
the Y5 receptor gene have been signiﬁcantly associated with panic
disorder (Domschke et al., 2008). Elevated plasma NPY was
detected in a study of individuals with panic disorder, in which the
authors suggest that an increase in NPY may be compensatory to
buffer enhanced sympathetic activation in this disorder (Boulenger
et al., 1996). Other studies have not detected differences in NPY
levels between healthy controls and persons with obsessive
compulsive, social anxiety, or panic disorders (Stein et al., 1996;
Altemus et al., 1999), or have failed to identify genetic associa-
tions between NPY and anxiety disorders (Lindberg et al., 2006).
3.2. Depression
Clinical investigations have revealed that the plasma and CSF of
depressed individuals contain decreased concentrations of NPY
compared to healthy controls (Hashimoto et al., 1996; Heilig et al.,
2004; Hou et al., 2006; Nilsson et al., 1996; Widerlov et al., 1988).
Additional studies have shown lower NPY in clinically depressed
patients with a history of suicide attempts compared to healthy
persons, and that NPY levels are lowest in individuals with a recent
suicide attempt (Westrin et al., 1999). Likewise, low NPY immu-
noreactivity has been found in postmortem brain tissue of suicide
victims, with the most robust reductions in NPY occurring in the
brains of persons with a history of depression (Widdowson et al.,
1992). Low levels of NPY mRNA expression are also found in per-
sons with bipolar disorder (Caberlotto and Hurd, 1999; Kuromitsu
et al., 2001). Genetic variants of the preproNPY gene have been
associated with resilience or vulnerability to depression (Heilig
et al., 2004; Wang et al., 2013; Sjoholm et al., 2009). For instance,
a genetic polymorphism resulting in higher levels of mature NPY
appears to be protective against depression despite exposure to
environmental risk factors (Sjoholm et al., 2009), and the presence
of this polymorphism is less frequent in depressed patients (Heilig
et al., 2004). In another study, a genotype associated with low NPY
expression was found to be overrepresented in persons with major
depression compared to healthy controls (Mickey et al., 2011).
Interestingly, antidepressant strategies are associated with parallel
elevations in NPY and decreases in corticotropin-releasing hor-
mone (CRH), thereby supporting peptidergic interactions in the
mechanisms underlying clinically efﬁcacious treatments for
depression. For example, CSF levels of NPY are elevated in
depressed patients following electroconvulsive therapy, while
levels of corticotropin-releasing hormone decrease concurrently
(Mathe et al., 1995; Nikisch and Mathe, 2008). Increased NPY after
treatment with the selective serotonin reuptake inhibitor cit-
alopram is associated with a reduction in depression severity and
the levels of CRH (Nikisch et al., 2005).
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Reduced concentrations of cerebrospinal and plasma NPY have
been reported in both individuals with PTSD and those who have
been exposed to traumatic stress (Sah et al., 2009; Rasmusson et al.,
2000; Morgan et al., 2003). NPY is inversely related to PTSD
symptomology, with low NPY correlating speciﬁcally to the pres-
ence of intrusion symptoms (Sah et al., 2014). Higher NPY is
predicative of PTSD symptom improvement and shows a positive
association with coping following a traumatic event (Yehuda et al.,
2006). Aberrant NPYand norepinephrine function have been linked
in PTSD. Yohimbine, an antagonist of the presynaptic a2-adrenergic
receptor that increases norepinephrine levels, elicits panic attacks
and exacerbates the core symptoms of PTSD (Bremner et al., 1997).
Yohimbine has also been shown to stimulate increases in plasma
NPYand levels of the norepinephrine metabolite MHPG (3-methyl-
4-hydroxy-phenyl-glycol) in healthy subjects. However,
yohimbine-stimulated increases in NPY are signiﬁcantly blunted in
persons with PTSD (Rasmusson et al., 2000; Rasmusson et al.,
1998). Additionally, baseline concentrations of plasma NPY corre-
lated negatively to yohimbine-induced increases in MHPG in the
same study (Rasmusson et al., 2000). This correlation suggests that
low basal levels of NPY were associated with an exaggerated in-
crease in MHPG following yohimbine (Rasmusson et al., 2000).
Both basal and yohimbine-stimulated levels of NPYwere negatively
correlated to scores on a combat-exposure scale, indicating that
greater combat exposure was associated with blunted levels of NPY
(Rasmusson et al., 2000).
4. Potential therapeutic applications of NPY: evidence from
animal models
Pathological responses to stress manifest in behaviors that
include enhanced anxiety, arousal, and fear. In this section, we re-
view the ﬁndings in animal models utilized to examine these three
behavioral responses, as well as the effects of NPY in rodent models
of PTSD and depression-like behavior. Examples provided in the
text are summarized in Table 1.
4.1. Anxiety
Genetic rodent models and pharmacological studies have pro-
vided insight into the anxiolytic properties of NPY in multiple
paradigms of anxiety-like behavior (Kask et al., 2002; Sajdyk et al.,
2004). NPY deﬁciency is associated with an anxiogenic phenotype
in rodents (Bannon et al., 2000), and highly anxious rats are more
sensitive to the anxiolytic actions of NPY (Sudakov et al., 2001).
Intracerebroventricular (i.c.v.) administration of NPY decreases
anxiety-like behavior in the elevated plus maze, Vogel's drinking
conﬂict test (Broqua et al., 1995; Heilig et al., 1989), and other op-
erant conﬂict tasks (Britton et al., 1997; Heilig et al., 1992). Site
speciﬁc-studies have revealed the amygdala, locus coeruleus,
lateral septum, and hippocampus as regions that are involved in the
anxiolytic properties of NPY (Lin et al., 2010; Thorsell et al., 2000;
Primeaux et al., 2005; Sajdyk et al., 1999; Heilig et al., 1993; Kask
et al., 1998a,b,c; Trent and Menard, 2011). For example, infusion
of NPY into the basolateral amygdala decreases social anxiety
(Sajdyk et al., 1999), produces anti-conﬂict effects via the central
nucleus of the amygdala (Heilig et al., 1993), and decreases anxiety
upon injection into the locus coeruleus (Kask et al., 1998a,b,c). The
effects of NPY may be related to interactions with CRF signaling, as
NPYattenuates anxiety and avoidance behavior induced by CRF and
CRF agonists upon i.c.v. or direct delivery into subregions of the
amygdala (Ide et al., 2013; Sajdyk et al., 2006; Britton et al., 2000).
An interaction with norepinephrine systems has also beenimplicated, as pretreatment with idazoxan, an a2-adrenergic re-
ceptor antagonist, blocks the anxiolytic effects of NPY (Heilig et al.,
1989).
The receptor subtypes mediating the anxiolytic properties of
NPYare currently under investigation. Studies largely support a role
for the activation of Y1R in the attenuation of anxiety-like behavior.
For example, the anxiolytic effects of NPYare absent in mice lacking
the Y1R (Karlsson et al., 2008; Heilig, 1995), and Y1R knockoutmice
exhibit an anxiogenic phenotype (Karl et al., 2006; Longo et al.,
2014). Selective knockout of Y1R from excitatory forebrain neu-
rons also results in increased anxiety (Bertocchi et al., 2011). Cen-
trally administered Y1R agonists are anxiolytic in a number of
behavioral paradigms (Britton et al., 1997; Sorensen et al., 2004),
while site-speciﬁc examinations implicate the central nucleus of
the amygdala and hippocampus as regions of Y1R-mediated anx-
iolysis (Heilig et al., 1993; Olesen et al., 2012; Lyons and Thiele,
2010). Administration of Y1R antagonists centrally or into the
periaqueductal grey produces anxiogenic effects (Kask et al.,
1998a,b,c), but has no reported effects when delivered into the
locus coeruleus, hypothalamus, or central nucleus of the amygdala
(Kask et al., 1998a,b,c). The lack of effect in these regions may be
due to their low level of expression of Y1R (Kask et al., 2002).
Central blockade of Y1R is also sufﬁcient to elicit conditioned place
aversion, supporting the notion that Y1R are necessary for endog-
enous anxiolytic actions of NPY (Kask et al., 1999). Y1R are found to
be preferentially expressed on pyramidal cells in the basolateral
amygdala (Rostkowski et al., 2009), therefore it is likely that Y1R
mediate anxiolysis here by inﬂuencing glutamatergic input to the
central nucleus of the amygdala and subsequent output to the
brainstem (Gilpin et al., 2011).
The function of Y2R in anxiety is allegedly opposite of the Y1R
subtype; however conﬂicting reports demonstrating both anxio-
genic and anxiolytic effects mediated by Y2R make the role of this
subtype in anxiety less clear. Y2R are generally considered NPY
autoreceptors and evidence for their pre-synaptic localization has
been demonstrated in humans and rodents (Stanic et al., 2011;
Caberlotto et al., 1998). Central administration of Y2R agonists
have failed to alter anxiety-like behavior in a number of studies
(Broqua et al., 1995; Heilig et al., 1989; Britton et al., 1997;
Sorensen et al., 2004). However, agonism of Y2R in the locus
coeruleus and lateral septum produces anxiolytic effects, whereas
Y2R are required for NPY-mediated anxiolysis in the hippocampus
(Kask et al., 1998a,b,c; Trent and Menard, 2013; Smialowska et al.,
2007). Y2R agonism in the basolateral amygdala has bidirectional
effects on anxiety in the social interaction test, with low agonist
doses generating anxiety and high doses decreasing anxiety
(Sajdyk et al., 2002). A recent study indicates that knockout of the
Y2R in GABAergic neurons located in the central nucleus of the
amygdala was anxiogenic speciﬁcally in female mice (McCall
et al., 2013). Contrasting reports indicate that Y2R antagonism
in the central nucleus of the amygdala is anxiolytic (Kallupi et al.,
2013), and that ablation of Y2R in either the basolateral or central
nucleus of the amygdala produces an anxiolytic phenotype (Tasan
et al., 2010). Global deletion of Y2R reduces anxiety in the
elevated plus maze, lightedark, open-ﬁeld, and marble burying
tests (Tasan et al., 2009; Painsipp et al., 2008; Painsipp et al.,
2008; Tschenett et al., 2003), and Y2R deﬁcient mice exhibit
reduced neuronal activation upon exposure to an anxiogenic
environment (Nguyen et al., 2009). Taken together, this evidence
suggests that Y2R may function in a regionally speciﬁc and neu-
rochemically selective fashion.
The Y4R and Y5R also have putative roles in rodent anxiety-like
behavior. Similar to Y2R mutant mice, deletion of the Y4R also re-
duces anxiety-like behavior in a number of rodent paradigms
(Tasan et al., 2009; Painsipp et al., 2008). Knockout of the Y4R with
Table 1
Behavioral observations following pharmacological interventions or genetic manipulations of the NPY system.
Rodent models Pharmacological
intervention or
genetic manipulation
Route of
administration/region
Direction of
behavioral
effect
Reference
Anxietyelike
Behavior
NPY i.c.v.
BLA, CeA
Hippocampus
Lateral Septum
LC
Decrease (Broqua et al., 1995; Heilig et al., 1989; Britton et al., 1997;
Heilig et al., 1992)
(Primeaux et al., 2005; Sajdyk et al., 1999;
Heilig et al., 1993)
(Lin et al., 2010; Thorsell et al., 2000)
(Trent and Menard, 2011)
(Kask et al., 1998)
NPY knockout Increase (Bannon et al., 2000)
Y1R agonists i.c.v.
CeA
Hippocampus
Decrease (Britton et al., 1997; Sorensen et al., 2004)
(Heilig et al., 1993; Lyons and Thiele, 2010)
(Olesen et al., 2012)
Y1R antagonists i.c.v.
PAG
LC
Hypothalamus
CeA
Increase
No effect
(Kask et al., 1998; Kask et al., 1998a,b,c; Kask et al., 1999)
(Kask et al., 1998)
Y1R knockout Increase (Karl et al., 2006; Longo et al., 2014; Bertocchi et al., 2011)
Y2R agonist i.c.v.
LC
Lateral septum
BLA (high dose)
No effect
Decrease
(Broqua et al., 1995; Heilig et al., 1989; Britton et al., 1997;
Sorensen et al., 2004)
(Kask et al., 1998)
(Trent and Menard, 2013)
(Sajdyk et al., 2002)
Y2R antagonists CeA Decrease (Kallupi et al., 2013)
Y2R knockout Global, BLA or CeA
GABAergic neurons
in CeA
Decrease
Increase
(Tasan et al., 2010; Tasan et al., 2009; Painsipp et al., 2008;
Painsipp et al., 2008; Tschenett et al., 2003)
(McCall et al., 2013)
Y4R knockout Decrease (Tasan et al., 2009; Painsipp et al., 2008)
Y5R agonist i.c.v. Decrease (Sorensen et al., 2004)
Y5R antagonist BLA Decrease (Sajdyk et al., 2002)
Arousal NPY i.c.v., BLA
CeA
Decrease
No effect
(Broqua et al., 1995; Gilpin et al., 2011;
Gutman et al., 2008)
(Gutman et al., 2008)
NPY knockout Increase (Sudakov et al., 2001)
Y1R agonists i.c.v. Decrease (Broqua et al., 1995)
Y2R i.c.v. No effect (Broqua et al., 1995)
Y2R knockout Increase (Sudakov et al., 2001)
Fear NPY i.c.v., Amygdala Decrease (Gutman et al., 2008; Lach de Lima, 2013;
Fendt et al., 2009; Pickens et al., 2009)
NPY knockout Increase (Verma et al., 2012)
Y1R agonists i.c.v. Decrease (Lach de Lima, 2013)
Y1R antagonists i.c.v.
Amygdala
Block NPY effects
Increase
(Lach de Lima, 2013)
(Gutman et al., 2008)
Y1R knockout Increase (Fendt et al., 2009)
Y2R knockout No effect (Verma et al., 2012)
Depressionelike
Behavior
NPY i.c.v., Hippocampus Decrease (Redrobe et al., 2005; Stogner and Holmes, 2000;
Redrobe et al., 2002; Ishida et al., 2007)
Y1R agonists i.c.v. Decrease (Redrobe et al., 2002)
Y1R antagonists i.c.v. Block NPY effects (Redrobe et al., 2002)
Y1R knockout Increase (Karlsson et al., 2008)
Y2R antagonists i.c.v. Decrease (Redrobe et al., 2002)
Y2R knockout Decrease (Painsipp et al., 2008)
Y4R knockout Decrease (Tasan et al., 2009; Painsipp et al., 2008)
Depression Models
(OBX or FSL)
NPY Decrease (OBX) (Goyal et al., 2009)
Y1R agonist i.c.v. Decrease (OBX) (Goyal et al., 2009)
Y2R agonist i.c.v. Increase (OBX) (Morales-Medina et al., 2012)
Y2R antagonist i.c.v. Decrease (OBX) (Morales-Medina et al., 2012)
Y5R antagonist i.c.v. Decrease (FSL) (Walker et al., 2009)
PTSD models
(PSS and SPS
NPY Intranasal,
Hippocampus
Decrease anxiety, arousal,
fear, depression-like
behaviors
(Cohen et al., 2012; Serova et al., 2013; Serova et al., 2014)
Y1R antagonist Hippocampus Increase anxiety, arousal (Cohen et al., 2012)
N.M. Enman et al. / Neurobiology of Stress 1 (2015) 33e4336the Y2R enhances the anxiolytic phenotype observed following
deletion of either receptor alone (Tasan et al., 2009). Finally, phar-
macological studies indicate that Y5R ligands may have promising
anxiolytic properties. A Y5R antagonist blocked the anxiolytic ef-
fects of a Y2R agonist in the basolateral amygdala (Sajdyk et al.,
2002), while i.c.v. delivery of a Y5R agonist produced anxiolytic
effects (Sorensen et al., 2004). Y5R can form heterodimers with Y1R
(Gehlert et al., 2007), and these receptor subtypes are colocalized inthe basolateral amygdala, hippocampus, and hypothalamus (Wolak
et al., 2003; Longo et al., 2014; Oberto et al., 2007; Fetissov et al.,
2004). Y1 and Y5 receptors act synergistically in the regulation of
energy homeostasis (Mashiko et al., 2009). Although the combined
effects of Y1 and Y5 receptor agonists have not been tested in the
context of anxiety thus far, the notion of co-activating these re-
ceptors could be valuable in the development of pharmacother-
apeutics for enhanced anxiolytic effects.
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Hypervigilance is a characteristic symptom of stress-related
psychiatric disorders that may reﬂect dysregulation of brain
arousal systems. Startle responses can bemeasured in rodents using
loud acoustic tones, and can be enhanced in fear-potentiated startle,
a paradigm in which startle is tested in an environment previously
paired with footshocks. Central administration of NPY inhibits both
basal acoustic startle and fear-potentiated startle in rodents (Broqua
et al., 1995; Gilpin et al., 2011; Gutman et al., 2008). Another study
demonstrated that NPY infusion into the basolateral, but not central
nucleus, of the amygdala mimics the effects of NPY on acoustic
startle and fear-potentiated responses (Gutman et al., 2008). Central
administration of a Y1R agonist attenuates fear-potentiated startle,
whereas a Y2R agonist was reported to have no effect (Broqua et al.,
1995). In genetically modiﬁed rodents, knockout of NPY or Y2R en-
hances acoustic startle (Bannonet al., 2000),whereas deletion of the
Y1R yields impaired habituation of startle responses (Karl et al.,
2010). These studies indicate a role for NPY in the modulation of
startle and potential for NPY as a therapeutic for hyperarousal in
stress-related psychiatric disorders. However the receptor subtypes
andbrain regionsdictatingNPY-induced resilience to this behavioral
response remain unclear. The NE system originating in the locus
coeruleus (LC) is a brainstem region contributing to arousal re-
sponses (Samuels and Szabadi, 2008; Sara and Bouret, 2012), thus
NPYmaymediate arousal behavior by directly acting in the LC or by
inﬂuencing brain regions upstream. Fig. 1 demonstrates putative
neurochemical interactions and circuitry that may inﬂuence the
function of the LC-NE system and arousal behavior. NPY inhibits the
ﬁring rate ofNEneurons in the LC, andpotentiates the effect ofNEon
presynaptic autoinhibition of neuronal ﬁring (Illes et al., 1993; Finta
et al., 1992). This electrophysiological evidence suggests that NPY
mayact to restrain the activity of noradrenergic neurons,whichmay
have important implications for stress-psychiatric diseases inwhich
the LC-NE system is disrupted. In combination with anatomical ev-
idence demonstrating rich NPY innervation of the LC (Smialowska,
1988) (shown in Fig. 2),these studies suggest that NPY may play an
important role in the regulation of noradrenergic stress responses
and arousal via NE circuitry.Fig. 1. Putative modulation of arousal behavior by NPY within stresseintegrative circ
activate the central nucleus of the amygdala (CeA) in response to stress. Subsequent activatio
of norepinephrine (NE) neurons in the locus coeruleus (LC), which then project to and acti
with stress responsive regions are shown. Activation of Y1 receptors on Glu neurons in the
NPY may suppress noradrenergic activation in the LC via Y2R located on NE neurons (Illes et
CeA leading to disinhibition of GABA output to the LC (not shown) (Gilpin, 2012). Alternativ
the CeA to suppress the activity of the LC-NE system in response to stress.4.3. Fear
Recent rodent studies suggest that NPY may be useful in the
treatment of psychiatric diseases such as PTSD, which is heavily
characterized by behavioral sequelae associated with fear. NPY has
been found to inﬂuence multiple fear-related behaviors including
the acquisition, incubation, expression, and extinction of condi-
tioned fear. For example, i.c.v. administration of NPY or a Y1R
agonist inhibits freezing behavior in both the acquisition and
consolidation phases of fear conditioning, and these effects are
blocked by pretreatment with a Y1R antagonist (Lach de Lima,
2013). Y1R may not be necessary for the cued-expression of fear,
as intra-amygdalar administration of NPY robustly decreases the
expression of conditioned fear, but these effects are not replicated
by Y1R agonists and are not blocked by pretreatment with a Y1R
antagonist (Fendt et al., 2009). In this particular study, Y1R
knockout mice showed slight elevations in freezing behavior dur-
ing fear conditioning, but did not show an enhanced phenotype
upon testing for the cued-expression of fear compared to wildtype
mice (Fendt et al., 2009). In addition, NPY was still capable of
reducing the cued-expression of fear in these Y1R deﬁcient mice,
suggesting that the Y1R may not be involved in this phase (Fendt
et al., 2009). NPY can suppress the long-term incubation of
conditioned fear, while delivery of NPY prior to extinction training
attenuates freezing and enhances retention of extinguished fear
memories (Gutman et al., 2008; Lach de Lima, 2013; Pickens et al.,
2009). Y1R antagonism blocks NPY-induced reductions in freezing
and blockade of amygdalar Y1R leads to deﬁcient extinction
retention (Gutman et al., 2008; Lach de Lima, 2013). Consistent
with pharmacological studies, NPY knockout mice display accel-
erated acquisition of conditioned fear, excessive recall of fear, and
impaired fear extinction (Verma et al., 2012). Interestingly, deletion
of the Y1R has moderately similar effects, whereas knockout of the
Y2R has no effect on fear (Verma et al., 2012). However, double Y1R
and Y2R knockout mice exhibit a remarkably similar phenotype to
NPY deﬁcientmice, indicating that both receptor subtypes do play a
role in aspects of fear conditioning (Verma et al., 2012). In an
inescapable footshock paradigm, interactions between the NPYand
CRF systems were evident as increased amygdalar CRFR1 anduitry. Excitatory glutamatergic (Glu) projections from the basolateral amygdala (BLA)
n of afferents expressing corticotropin-releasing factor (CRF) leads to enhanced activity
vate regions of the forebrain to regulate arousal behavior. Putative interactions of NPY
BLA may decrease activation of the CeA in response to stress (Rostkowski et al., 2009).
al., 1993; Finta et al., 1992), or suppress Y2R-expressing GABAergic interneurons in the
ely, we hypothesize that NPY axon terminals may directly interact with CRF neurons in
Fig. 2. NPY innervation of the rat locus coeruleus. NPY ﬁbers (green) innervating the nuclear core (A) and the ventral dendritic region (B) of the locus coeruleus are shown.
Noreprinephrine neurons in the locus coeruleus are represented by staining of the biosynthetic enzyme tyrosine hydroxylase (TH) (red). Colocalization of NPY and TH can be
observed in cell bodies and ﬁbers (yellow). NPY and TH in this high magniﬁcation image were visualized by immunoﬂuorescence and confocal laser microscopy. Tissues were
obtained from a non-colchicine treated SpragueeDawley rat, which may contribute to the minimal observation of NPY synthesizing neurons in this image. (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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playing enhanced freezing time, and all of these effects were
reversed in parallel following re-exposure to the footshock-paired
environment (Hendriksen et al., 2012). Indirect evidence for NPY
interactions with norepinephrine was obtained using auditory fear
conditioning, in which centrally administered NPY and a Y1R
agonist blunted fear-induced tachycardia (Tovote et al., 2004).
These effects were blocked by a Y1R antagonist (Tovote et al., 2004).4.4. Rodent models of depression
NPY is implicated in depression-like behavior and produces
antidepressant effects. For example, central administration of NPY
dose-dependently reduces immobility and increases swimming
time in the forced swim test (Redrobe et al., 2005; Stogner and
Holmes, 2000; Redrobe et al., 2002), a screening paradigm for
pharmacological anti-depressant activity. Y1R agonists and Y2R
antagonists also produce anti-depressant effects in forced swim
(Redrobe et al., 2002), whereas Y1R antagonists block the anti-
depressant effects of NPY (Redrobe et al., 2002). Intra-
hippocampal infusion of NPY has anti-depressant properties in a
learned helplessness paradigm, which is blocked by co-
administration of a Y1R, but not a Y2R antagonist (Ishida et al.,
2007). Y1R knockout mice display increased immobility in the
forced swim test, indicative of a depression-like phenotype
(Karlsson et al., 2008). Both Y2R and Y4R knockout mice exhibit
reduced depression-like behavior in the tail suspension test,
another common screening assay for antidepressant potential
(Tasan et al., 2009; Painsipp et al., 2008; Painsipp et al., 2008).
Knockout of both Y2R and Y4R results in augmented anti-
depressant effects compared to single-knockout of either receptor
(Tasan et al., 2009). Anti-depressant strategies including imipra-
mine and electroconvulsive stimuli increase NPY immunoreactivity
or receptor mRNA and binding sites, respectively (Heilig et al., 1988;
Madsen et al., 2000). The anti-depressant properties of NPYmay be
mediated through interactions with the serotonin system, as
administration of a tryptophan hydroxylase inhibitor blocked the
anti-depressant effects of NPY in the forced swim test (Redrobe
et al., 2005).
The Flinders-sensitive line (FSL) is a transgenic model of
depression in which abnormalities in NPY, serotonin, andcatecholaminergic systems have been identiﬁed (Overstreet et al.,
2005; Serova et al., 1998). Depression-like behavior has been
associated with impaired hippocampal neurogenesis, and
enhanced NPY and serotonin activities been shown to increase cell
proliferation in the dentate gyrus of the hippocampus (Husum
et al., 2006). Hippocampal and amygdalar NPY immunoreactivity
is lower in FSL rats compared to Flinders-resistant controls
(Jimenez Vasquez et al., 2000; Jimenez-Vasquez et al., 2000;
Zambello et al., 2008), and aging is associatedwith exacerbated loss
of hippocampal NPY immunoreactivity in the FSL line (Husum et al.,
2006). In FSL rats, Y5R antagonism produces anti-depressant effects
in the forced swim test (Walker et al., 2009). Electroconvulsive
stimuli and the selective serotonin reuptake inhibitor ﬂuoxetine
increase NPY mRNA or immunoreactivity in the hippocampus and
hypothalamus, and upregulate amygdalar Y1R binding sites in FSL
rats (Caberlotto et al., 1998; Caberlotto et al., 1999). Exercise and
escitalopram are associatedwith similar alterations in hippocampal
NPY and Y1 receptor mRNA (Bjornebekk et al., 2010). NPY has also
been examined in olfactory bulbectomized rats (OBX), which are
utilized as a rodent model due to depression-like disruptions in
behavior, physiology, and neurochemistry (Song and Leonard,
2005; Kelly et al., 1997). Anti-depressant effects are observed
following chronic treatment with NPY, a Y1R agonist, and a Y2R
antagonist in OBX rats (Goyal et al., 2009; Morales-Medina et al.,
2012). In contrast, chronic administration of a Y2R agonist
enhanced depression-like behavior in OBX rats in the forced swim
test (Morales-Medina et al., 2012).
Future studies investigating the efﬁcacy of NPY in depression-
like behavior induced by chronic psychosocial stress using the
resident-intruder model of social defeat would be interesting. So-
cial defeat reproduces behavioral and physiological indices of
depression including disruption of CRF and NE systems (Wood
et al., 2010; Wood, 2014; Chaijale et al., 2014; Chaijale et al.,
2013; Russo et al., 2012), and would likely yield important infor-
mation regarding the role of NPY in depressive behavior and
disorders.4.5. Rodent models of PTSD
Several rodent models of PTSD indicate that NPY expression in
the brain following stress may be associated with susceptibility to
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extreme anxiety and arousal following exposure to predator scent
stress (PSS) had lower NPY protein levels in the cortex, amygdala,
hippocampus, and periaqueductal grey compared to rodents that
were less impaired or to unstressed controls (Cohen et al., 2012).
Injection of NPY into the hippocampus 1 h after PSS reduced the
development of anxiety-like behavior, hyperarousal, and cue-
elicited freezing. Additionally, NPY administration reduced the
prevalence of an extreme behavioral response (Cohen et al., 2012).
Delivery of NPY to the brain by intranasal (IN) infusion has been
used to examine its efﬁcacy in the single prolonged stress (SPS)
model of PTSD (Serova et al., 2013; Laukova et al., in press; Serova
et al., 2014). Intranasal NPY can elevate CSF concentrations to a
range that reduces anxiety behavior after i.c.v. administration,
while also reaching multiple stress responsive brain regions and
leaving plasma NPY levels unchanged (Serova et al., 2013; Laukova
et al., in press). Pretreatment with IN NPY slowed the development
of immobility during the forced swim portion of SPS, and reduced
the induction of gene expression of the NE biosynthetic enzymes,
tyrosine hydroxylase and dopamine beta hydroxylase, in the locus
coeruleus shortly after SPS (Serova et al., 2013). SPS-induced in-
creases in plasma corticosterone and ACTHwere also attenuated by
IN NPY, suggesting either less activation or more rapid recovery of
the hypothalamic-pituitary-adrenal (HPA) axis (Serova et al., 2013).
Intranasal NPYadministered prior to or immediately after SPS led to
pronounced and long-lasting effects on the development of
behavioral, neuroendocrine, andmolecular impairments associated
with PTSD. NPY greatly attenuated, and in many cases prevented,
increases in anxiety, hyperarousal, and depression-like behavior
observed 1e2 weeks after exposure to traumatic stress (Serova
et al., 2013). NPY prevented SPS-triggered induction of CRF, gluco-
corticoid receptor (GR), and FKBP5 mRNAs and the reduction in
phosphorylated-GR in the mediobasal hypothalamus (Laukova
et al., in press). NPY also increased the expression and phosphor-
ylation of GR in the hippocampus (Laukova et al., in press). These
studies suggest that early intervention with intranasal NPY may
prevent dysregulation of the HPA axis by restoring proper negative
feedback inhibition by GR. Intranasal NPY also attenuated long-
term changes in the central noradrenergic system induced by
SPS, including the development of increased sensitization of the LC
to re-experiencing the forced swim (Serova et al., 2013). Taken
together, PSS and SPS studies indicate that a single treatment with
NPY near the time of the traumatic stress could provide long-
lasting resilience to the development of PTSD and co-morbid im-
pairments such as depression. Moreover, recent work also suggests
that NPY may be efﬁcacious as a treatment once PTSD-like symp-
toms have already manifested. Rats given IN NPY one week after
SPS, when PTSD-like symptoms have manifested, exhibit anxiety-
like behavior similar to unstressed controls up to 2 days later
(Serova et al., 2014). Rats administered NPY after SPS also had
reduced depression-like behavior (Serova et al., 2014). Further
studies are necessary to determine if intranasal NPY reverses other
impairments associated with PTSD, as well as the duration and
sustainability of the improvements.
5. Therapeutic implications
The examples presented herein demonstrate that pharmaco-
logical interventions targeting the NPY system display much
promise for the treatment of numerous stress-related psychiatric
disorders. Future pharmacotherapeutic studies should consider
targeting the central NPY system in stress-related emotionality and
resilience. The preponderance of data suggests that NPY itself has
signiﬁcant therapeutic potential as a mediator of stress resilience.
There are twomajor challenges associated with the development ofNPY as a drug for psychiatric disorders; it is a peptide and it has a
broad range of activities that may result in undesirable side-effects.
The attractiveness and challenges of peptide therapeutics for CNS
disorders has recently been reviewed (McGonigle, 2012). Peptides
do not accumulate in tissues and are effectively metabolized by
endogenous enzymes; therefore they have limited potential for
drugedrug interactions. However, peptides have short half-lives
and several methods have been introduced to prolong their sta-
bility in vivo. Encouragingly, as demonstrated in rodent models
(Serova et al., 2013; Laukova et al., in press; Serova et al., 2014), NPY
may confer long-lasting beneﬁts for stress resilience despite its
short half-life.
Although this review has concentrated on the beneﬁcial effects
of NPY in the CNS, NPY also has multiple actions in the periphery
(Hirsch and Zukowska, 2012; Held et al., 2006; Pedrazzini et al.,
2003). For example, NPY is a co-transmitter in sympathetic
nerves, plays a role in vascular tone, and contributes to cardiovas-
cular remodeling (Zukowska-Grojec, 1995; Edvinsson et al., 1984;
Schuerch et al., 1998; Abe et al., 2007). Rodent studies have
demonstrated NPY-induced disruption of metabolic homeostasis,
as chronic NPY administration in rodents leads to abnormal bar-
oreﬂex sensitivity, abdominal obesity, and dyslipidemia (Xie et al.,
2012). NPY release from sympathetic nerves also stimulates fat
angiogenesis, macrophage inﬁltration, and proliferation and dif-
ferentiation of new adipocytes leading to abdominal obesity and a
metabolic syndrome in rodents (Kuo et al., 2007). NPY also plays a
role in bone physiology, gastrointestinal function, and cancer pro-
gression (Brothers and Wahlestedt, 2010). Peripheral administra-
tion of NPY may result in undesirable side effects on these
physiological processes, increasing the value and necessity for
strategies of NPYadministration to the brain. Moreover, peptides do
not typically cross the bloodebrain barrier unless carried by spe-
ciﬁc transporters. Although no such transporter is known to exist
for NPY, studies have shown that NPY can enter the brain to some
extent (Kastin and Akerstrom, 1999).
Intranasal (IN) infusion represents a clinically relevant and non-
invasive approach for the delivery of NPY to the brain. IN admin-
istration allows peptides to rapidly and directly enter the CNS via
intracellular neuronal olfactory and extracellular trigeminal-
associated pathways bypassing the bloodebrain barrier to affect
multiple sites within the brain (Dhuria et al., 2010; Ionescu et al.,
2012; Thorne et al., 1995; Thorne et al., 2004). As demonstrated
in rodentmodels (Serova et al., 2013; Laukova et al., in press; Serova
et al., 2014), NPY delivered to the brain by IN infusion has beneﬁcial
effects on stress-related emotionality and pathology, which is likely
achieved by inﬂuencing NPY responsive systems in all regions
regulating stress responses. A potential disadvantage of IN infusion
is the lack of selective targeting and potential for CNS-mediated
side effects. For example, NPY is also a powerful orexigenic agent
and regulates circadian rhythms (Brothers and Wahlestedt, 2010;
Gehlert, 1999). Although not used for stress-related implications,
studies have administered NPY by IN infusion in humans (Lacroix
and Mosimann, 1996; Lacroix et al., 1996; Cervin et al., 1999;
Hallschmid et al., 2003; Hallschmid et al., 2004). One small clin-
ical trial aimed to test the effect of IN NPY on mood and anxiety
(NCT 00748956) (U.S. National Institutes of Health, 2000a,b) while
another is currently underway to investigate the safety of IN NPY
using a dose escalation in PTSD (NCT 01533519) (U.S. National
Institutes of Health, 2000a,b). To date no side effects have been
reported. The viability of this route of administration makes it
much more feasible to consider clinical proof of concept studies for
severe stress-related disorders such as PTSD, for which there are no
truly effective treatments and the initiating stress is often known.
In the event that CNS-mediated side effects prove to be signiﬁcant
obstacles to the chronic use of NPY as a therapeutic, it is possible
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subtypes may be a safer yet still effective alternative. There is
already considerable preclinical data demonstrating the thera-
peutic potential of Y1R agonists and Y2R antagonists for the
treatment of stress-related disorders and these targets clearlymerit
additional study.
6. Future directions
Elucidating the neuroanatomical interactions of the NPY system
with other neurotransmitters and peptides within stress-
integrative circuitry would greatly advance our knowledge
regarding the role of NPY in stress resilience and emotionality in
future studies. In addition, future studies should consider the
impact of sex differences on NPY-mediated effects. Human and
rodent studies indicate that females may be more vulnerable to
stress and stress-related psychiatric diseases thanmales (Bangasser
and Valentino, 2014). Psychiatric symptomology and treatments
responses also vary based on sex (Kokras and Dalla, 2014). Future
studies examining the efﬁcacy of NPY on stress and emotionality in
females with direct comparisons to males would advance our un-
derstanding of sex differences in stress resilience. Neuroanatomical
and molecular studies conducted across sexes would reveal po-
tential mechanisms underlying effective coping to stress and
intervention strategies for stress-induced psychiatric diseases.
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